Pazopanib ameliorates rotenone-induced Parkinsonism in rats by suppressing multiple regulated cell death mechanisms
Food and Chemical Toxicology · 2023
DOI: 10.1016/j.fct.2023.114069 ↗Kurz gefasst
Fachartikel in der Zeitschrift Food and Chemical Toxicology, 2023. Verfasst von Heba M Mansour und 3 weiteren Autor:innen. Beteiligte Einrichtung: Central Administration of Biological, Innovative Products, and Clinical Studies, Egyptian Drug Authority, EDA, Giza, Egypt. Hauptthemen laut MEDLINE: Parkinsonian Disorders, Parkinson Disease, Ferroptosis. Die Arbeit wurde bisher 19-mal zitiert (Crossref) und nennt 87 Literaturangaben. Gefördert von: Al-Azhar University.
Abstract (Originalsprache)
Parkinson's disease (PD) is characterized by motor impairments and progressive dopaminergic neuronal death in the substantia nigra (SN). Recently, the involvement of other regulated cell death (RCD) machineries has been highlighted in PD. Necroptosis is controlled by p-RIPK1, p-RIPK3, and p-MLKL and negatively regulated by caspase-8. Ferroptosis is characterized by iron overload and accumulation of reactive oxygen species. Interestingly, the molecular chaperone complex HSP90/CDC37 has been reported to directly regulate necroptosis, ferroptosis, and some PD-associated proteins. We investigated the potential anti-necroptotic and anti-ferroptotic effects of the anti-cancer drug pazopanib, uncovering the HSP90/CDC37 complex as a master RCD modulator in rotenone-induced Parkinsonism in rats. Oral administration of 15 mg/kg pazopanib to rotenone-intoxicated rats for three weeks improved motor deficits, debilitated histopathological changes, and increased striatal dopaminergic levels. Pazopanib suppressed LRRK2 and c-Abl. Pazopanib displayed an anti-necroptotic effect through inhibition of the p-RIPK1/p-RIPK3/p-MLKL pathway and activation of caspase-8. Moreover, pazopanib inhibited the ferroptotic p-VEGFR2-PKCβII-PLC-γ-ACSL-4 pathway, iron, 4-HNE, and PTGS2 while increasing GPX-4 and GSH levels. Taken together, the current research sheds light on the repositioning of pazopanib targeting HSP90/CDC37 and its multiple RCD mechanisms, which would offer a new perspective for therapeutic strategies in PD.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Central Administration of Biological, Innovative Products, and Clinical Studies, Egyptian Drug Authority, EDA, Giza, Egypt.
- Department of Pharmacology and Toxicology, Faculty of Pharmacy, Cairo University, Cairo, Egypt; Faculty of Pharmacy, King Salman International University (KSIU), South Sinai, 46612, Egypt. Electronic address: Ahmed.fath…
- Department of Pharmacology and Toxicology, Faculty of Pharmacy, Cairo University, Cairo, Egypt.
Förderung
- Al-Azhar University
Zitieren
APA
Mansour, H. M., Mohamed, A. F., Khattab, M. M., & El-Khatib, A. S. (2023). Pazopanib ameliorates rotenone-induced Parkinsonism in rats by suppressing multiple regulated cell death mechanisms. Food and Chemical Toxicology. https://doi.org/10.1016/j.fct.2023.114069
Vancouver
Mansour HM, Mohamed AF, Khattab MM, El-Khatib AS. Pazopanib ameliorates rotenone-induced Parkinsonism in rats by suppressing multiple regulated cell death mechanisms. Food and Chemical Toxicology. 2023. doi:10.1016/j.fct.2023.114069
BibTeX
@article{Mansour2023,
author = {Mansour, Heba M and Mohamed, Ahmed F and Khattab, Mahmoud M and El-Khatib, Aiman S},
title = {Pazopanib ameliorates rotenone-induced Parkinsonism in rats by suppressing multiple regulated cell death mechanisms},
journal = {Food and Chemical Toxicology},
year = {2023},
doi = {10.1016/j.fct.2023.114069}
}
EUVIMED